FrancophonIA/ELRC3.0 huggingface dataset:
English: Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritability
Maltese: Depressjoni, ostilità/ aggressjoni, anzjetà, insomnja,
English: Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to
Maltese: Ir-reazzjonijiet avversi kienu ppreżentati f'ordni ta' gravita` minn ħafna għal ftit u il-frekwenza giet mfissra b'dan il-mod: komuni hafna (≥ 1/10); komuni: (> 1/100 sa < 1/10); mhux komuni: (> 1/1,000 sa < 1/100)u rari: (≥ 1/10,000 sa < 1/1,000); rari ħafna: (< 1/10,000).
English: Adults and adolescents
Maltese: Adulti u adoloxxenti Assorbiment
English: ks = 0.45 in Term infants to 1 year old; ks = 0.55 in Children to less than 13 years and in adolescent female; ks = 0.7 in adolescent male
Maltese: ks= 0.45 f'Trabi li twieldu fiż-żmien sa età ta' sena; ks= 0.55 fi tfal sa inqas minn 13-il sena u fl-adoloxxenti feminili; ks= 0.7 f'adoloxxenti maskili.
English: In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 AND UGT1A6) and epoxide hydroxylase activities.
Maltese: In vitro, kemm levetiracetam u kemm il-prodott ewlieni tal-metabolożmu ma fixklux l-iżoformi taċ-ċitokromju P450 fil-fwied ( CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 u 1A2), glucuronyl transferase
English: The results are consistent across age group.
Maltese: Ir-riżultati kienu konsistenti fil-gruppi tal-età.
English: • Dose in adults and adolescents (from 16 years of age):
Maltese: • Doża fl-adulti u adoloxxenti (minn 16-il sena):
English: Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified.
Maltese: Levitiracetam 2,000 mg kuljum ma kellux effett fuq il-farmakokinetika ta' digoxin u warfarin; il-prothrombin times ma kinux mibdulin.
English: • severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke's oedema [swelling of the face, lips, tongue and throat]);
Maltese: • reazzjonijiet allerġiċi serji (DRESS, reazzjoni anafillattika [reazzjoni severa u importanti], edima ta' Quinke [nefħa fil-wiċċ, xofftejn, ilsien u griżmejn]);
English: Asthenia/fatigue
Maltese: nervożità/irritabiltà
English: Levetiracetam Teva 500 mg contains Tartrazine
Maltese: Levetiracetam Teva 500 mg fih Tartrazine
English: 750 mg film-coated tablets: iron oxide yellow (E172), iron oxide red (E172) and sunset yellow FCF (E110).
Maltese: 750 mg pilloli miksija b'rita: iron oxide yellow (E172), iron oxide red (E172) u sunset yellow FCF (E110).
English: • on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
Maltese: • waħdu f'adulti u adoloxxenti minn 16-il sena b'epilessija li għadha kif ġiet iddijanjostikata, fit trattament ta' ċertu forma ta' epilessija.
English: Pack sizes of 20, 30, 50, 60, 100, 120 and 200 film-coated tablets and 50 x 1 film-coated tablets in PVC/PVdC - aluminium perforated unit dose blisters.
Maltese: Il-pakketti fihom 20, 30, 50, 60,100, 120 u 200 pillola miksija b'rita u pilloli miskija b'rita 50 x 1 f'folji tal-PVC/PVdC - aluminju maqsumin b'dożi singoli.
English: CLcr (ml/min/1.73 m2 = Height (cm) x ks____
Maltese: CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73 BSA pazjent (m2)
English: In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines.
Maltese: Huwa wkoll jaqleb parzjalment it-tnaqqis f'kurrenti gated b'GABA u glycine indotti b'żingu u ß-carbolines.
English: Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.
Maltese: Tagħrif minn studji kliniċi f'adulti li saru qabel ma ħareġ fis-suq, juri li levetiracetam ma kellu ebda effett fuq il-konċentrazzjonijiet ta' mediċini eżistenti kontra l-epilessija (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin u primidone), u li dawn il-prodotti ma kellhom ebda effett fuq il-profil farmakokinetiku ta' levetiracetam.
English: Add-on therapy for infants aged 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg
Maltese: Terapija miżjuda fit-trabi ta' età ta' 6 sa 23 xahar, tfal (2 sa 11-il sena) u adoloxxenti (12 sa 17-il sena) li jiżnu inqas minn 50 kg
English: The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).
Maltese: Ir-riżultati farmakokinetiċi wrew li l-half-life kien iqsar (5.3 h) minn dak fl-adulti (7.2 h) u l-tneħħija li deher kien iżjed mgħaġġel ( 1.5 ml/min/kg) minn dak fl adulti (0.96 ml/min/kg).
English: Levetiracetam Teva are available in pack sizes of 20, 30, 50, 60, 100, 120 and 200 film-coated tablets and 50 x 1 film-coated tablets in PVC/PVdC - aluminium perforated unit dose blisters.
Maltese: Levetiracetam Teva huma disponibbli f'pakketti ta' 20, 30, 50, 60, 100, 120 u 200 pillola miksija b'rita u pilloli 50 x 1 miskijin b'rita f'folji tal-PVC/PVdC - aluminju pperforati għal dożi singoli.
English: It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population.
Maltese: Kien konkluż li levetiracetam ma kienx differenti (mhux inferjuri) mill-plaċebo fejn jidħol il-bidla mill-linja bażi tal-Leiter-R Attention and Memory, Memory Screen Composite score fil-popolazzjoni skont il-protokol.
English: Levetiracetam Teva 1000 mg film-coated tablets Hypromellose 6 cp, Titanium dioxide (E171), Macrogol 3350
Maltese: Levetiracetam Teva 1000 mg pilloli miksija b'rita Hypromellose 6 cp, Titanium dioxide (E171), Macrogol 3350
English: Tablet coating: hypromellose 6 cp, titanium dioxide (E171), macrogol 3350, colourants*
Maltese: Il-kisja tal-pillola: hypromellose 6 cp, titanium dioxide (E171), macrogol 3350, colourants*
English: Age also had an influence on both parameters.
Maltese: L-età kellha wkoll effett fuq iż-żewġt parametri.
English: In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks.
Maltese: F'pazjenti pedjatriċi (4 sa 16-il sena), l-effiċjenza ta' levetiracetam kien muri fi studju double-blind ikkontrollat minn plaċebo li inkluda 198 pazjent b'trattament li dam 14-il ġimgħa.
English: A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study.
Maltese: Doża ta' 20 mg/kg/ġurnata sa 40 mg/kg/ġurnata għal trabi ta' xahar sa inqas minn sitt xhur u doża ta' 25 mg/kg/ġurnata sa 50 mg/kg/ġurnata għal trabi u tfal minn 6 xhur sa inqas minn 4snin ta' età, kienu użati f'dan l-istudju.
English: The NOAEL was < 200 mg/kg/day for the dams and 200 mg/kg/day for the foetuses (equal to the MRHD on a mg/m2 basis).
Maltese: In-NOAEL kien ta' <200 mg/kg/ġurnata fl-ommijiet u 200 mg/kg/ġurnata għal-feti (ugwali għal MRHD fuq bażi ta' mg/m2).
English: A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day.
Maltese: Studju fuq l-iżvilupp li sar waqt u wara t-tqala sar fil-firien b'dożi ta' levetiracetam ta' 70, 350 u 1800 mg/kg/ġurnata.
English: This medicinal product contains colouring agent tartrazine (E102) which may cause allergic reactions.
Maltese: Dan il-prodott mediċinali fih sustanza koloranti tartrazine (E102) li tista' tikkawża reazzjonijiet allerġiċi.
English: The dialyser extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite.
Maltese: L-effiċjenza tal-estrazzjoni tad-dijaliżi hija ta' 60 % għal levetiracetam u ta' 74 % għall-prodott ewlieni tal-metaboliżmu.
English: With continued long-term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure-free for at least 1 year.
Maltese: Bi trattament li jikompla fit-tul, 11.4 % tal-pazjenti ma kellhomx aċċessjonijiet għal mill-inqas 6 xhur u 7.2 % ma kellhomx aċċessjonijiet għal mill-inqas sena.
English: • muscle weakness, myalgia (muscle pain);
Maltese: • telf ta' xahar, ekżema, ħakk; • debolezza fil-muskoli, mijalġja (uġigħ fil-muskoli);
English: In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile.
Maltese: 1.7%), aggressjoni (komuni, 8.2%), mġieba abnormali (komuni, 5.6%), u telqa (komuni, 3.9%) kienu rappurtati iżjed frekwentament minn gruppi ta' etajjiet oħra jew mill-profil ta' sigurta` totali.
English: This medicinal product contains colouring agent sunset yellow (E110) which may cause allergic reactions.
Maltese: Dan il-prodott mediċinali fih sustanza koloranti sunset yellow (E110) li tista' tikkawża reazzjonijiet allerġiċi.
English: Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL - Achenbach Child Behaviour Checklist).
Maltese: Riżultati li għandhom x'jaqsmu mal-funzjoni tal-imġiba u dik emozjonali juru aggravament fil-pazjenti trattati b'levetiracetam f'imġiba aggressiva kif imkejjel b'mod standardizzat u sistematiku bl-użu ta' strument validat (CBCL - Achenbach Child Behaviour Checklist).
English: The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula):
Maltese: Il-CLcr f'ml/min/1.73 m2 tista' tigi kkalkulata mill-livell ta' kreatinina fis-serum (mg/dl), għal addoloxenti żgħar, tfal u trabi, billi tuża din il-formula (formula ta' Schwartz):
English: 20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 50x1 film-coated tablet 60 film-coated tablets 100 film-coated tablets 120 film-coated tablets 200 film-coated tablets
Maltese: 20 pillola miksija b'rita 30 pillola miksija b'rita 50 pillola miksija b'rita 50x1 pillola miksija b'rita 60 pillola miksija b'rita 100 pillola miksija b'rita 120 pillola miksija b'rita 200 pillola miksija b'rita
English: Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours.
Maltese: Wara li ngħatat doża orali waħda li tammonta għal 20 mg/kg lil tfal bl-epilessija (6 sa 12 il-sena), il-half life ta' levetiracetam kienet 6.0 sigħat.
English: • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Maltese: • Fit-trattament ta' aċċessjonijiet primarji u ġeneralizzati tat-tip tonic-clonic f'adulti u adoloxxenti minn 12-il sena b'Epilessija Ġeneralizzata Idjopatika.
English: Film-coated tablet
Maltese: żieda fil-piz
English: In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6 % for patients on placebo.
Maltese: 27.7 %, 31.6 % u 41.3 % għal pazjenti fuq 1000, 2000, jew 3000 mg ta' levetiracetam rispettivament u ta' 12.6 % għal pazjenti fuq il-plaċebo.
English: Rhabdomyolysis and blood creatine phosphokinase increased*
Maltese: Rabdomijolożi u żieda fil-creatinine phosphokinase fiddemm*
English: Levetiracetam Teva 250 mg film-coated tablets Levetiracetam Teva 500 mg film-coated tablets Levetiracetam Teva 750 mg film-coated tablets Levetiracetam Teva 1,000 mg film-coated tablets levetiracetam
Maltese: Levetiracetam Teva 250 mg pilloli miksija b'rita Levetiracetam Teva 500 mg pilloli miksija b'rita Levetiracetam Teva 750 mg pilloli miksija b'rita Levetiracetam Teva 1000 mg pilloli miksija b'rita
English: The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.
Maltese: Il-profil ta' sigurta` ta' levitiracetam huwa ġeneralment simili fil-gruppi kollha ta' l-etajjiet (adulti u pażjenti pedjatriċi) u fl-indikazzjonijiet approvati ta' epilessija kollha.
English: Levetiracetam Teva is used:
Maltese: - Is-sustanzi l-oħra huma:
English: With continued long-term treatment, 47.4 % of the patients were free of tonic-clonic seizures for at least 6 months and 31.5 % were free of tonic-clonic seizures for at least 1 year.
Maltese: 4 % tal-pazjenti ma kellhomx aċċessjonijiet tat-tip tonic-clonic għal mill-inqas 6 xhur u 31.5 % ma kellhomx aċċessjonijiet tat-tip tonic-clonic għal mill-inqas sena.
English: The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2
Maltese: The NAOEL (Livell ta'Ebda Effett Avvers Osservat) kien ta' 3600 mg/kg/ġurnata għal firien feminili tqal ( x12 il-MRHD
English: Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening).
Maltese: L-effikaċja ta' levetiracetam kienet stabbilita fi studju double-blind, ikkontrollat minn plaċebo ta' 24 ġimgħa, li inkludiet adulti, adoloxxenti u numru limitat ta' tfal b'epilessija tat-tip ġeneralizzata idjopatika b'aċċessjonijiet ġeneralizzati primarji tat-tip tonic -clonic (PGTC) f'sindromi ( epilessija mijoklonika li tibda fiż-żgħożija, epilessija tat-tip absence li tibda fiż-żgħożija, epilessija tat-tip absence fit-tfal, jew epilessija b'aċċessjonijiet Grand Mal meta jqumu).
English: In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks.
Maltese: F'adulti, l-effiċjenza ta' levetiracetam kien muri fi 3 studji double-blind ikkontrollati minn plaċebo f dożi ta' 1000 mg, 2000 mg, jew 3000 mg/ kuljum, mogħtija f'2 dożi separati, b'trattament li dam sa 18 il-ġimgħa.
English: Creatinine clearance (ml/min/1.73 m2)
Maltese: Rata ta' tneħħija tal kreatinina (ml/min/1.73 m2)
English: • Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more:
Maltese: • Dożaġġ f'adulti u adoloxxenti (minn 12 sa 17-il sena) li jiżnu 50 kg jew iżjed:
English: The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam.
Maltese: Il-profil tar-reazzjonijiet avversi ppreżentati hawn taħt huwa bbażati fuq l-analiżi ta' ġabra ta' provi kliniċi kkontrollati bil-plaċebo fejn ġew studjati l-indikazzjonijiet kollha, b'total ta' 3,416 pazjent trattati b'levetiracetam.
English: 7 to 21 mg/kg twice daily
Maltese: 7 sa 21 mg/kg darbtejn kuljum
English: • rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase.
Maltese: • rabdomilożi (it-tkissir tat-tessut tal-muskoli) u żieda assoċjata fil-creatinine phosphokinase fid demm.
English: Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day.
Maltese: Erba' studji dwar l-iżvilupp tal-embriju u l-fetu saru fil-fniek li koprew dożi ta' 200, 600, 800, 1200 u 1800 mg/kg/ġurnata.
English: With continued long-term treatment, 28.6 % of the patients were free of myoclonic seizures for at least 6 months and 21.0 % were free of myoclonic seizures for at least 1 year.
Maltese: B'trattament li jitkompla fit-tul, 28.6 % tal-pazjenti ma kellhomx aċċessjonjiet mijokloniċi għal mill-inqas 6 xhur u 21.0 % ma kellhomx aċċessjonjiet mijokloniċi għal mill-inqas sena.
English: The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.
Maltese: Is-sustanza attiva, levetiracetam hija derivattiva ta' pyrrolidone (S-enantiomer ta' α-ethyl-2- oxo-1
English: Talk to your doctor before taking Levetiracetam Teva
Maltese: Mediċini oħra u Levetiracetam Teva
English: 3.5 to 7 mg/kg twice daily
Maltese: 3.5 sa 7 mg/kg darbtejn kuljum
English: In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule.
Maltese: 25 mg/kg, 40 mg/kg jew 50 mg/kg ta' soluzzjoni orali bbażati fuq l-iskeda tat-titrazzjoni skont l-età.
English: Completed suicide, personality disorder, thinking abnormal, delirium
Maltese: Suwiċidju li jsir, mard tal-personalità, ħsibijiet abnormali, delirju
English: • sudden decrease in kidney function;
Maltese: • tnaqqis f'daqqa fil-funzjoni tal-kliewi;
English: Add-on therapy for adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more
Maltese: Terapija miżjuda għal adulti (≥18 sena ) u adoloxxenti (12 sa 17-il sena) li jiżnu iżjed minn 50 kg jew iżjed.
English: Suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state , panic attack, affect lability/mood swings, agitation
Maltese: • attentat ta' suwiċidju u ħsibijiet ta' suwiċidju, mġieba abnormali, alluċinazzjonijiet, rabja, konfużjoni, attakk ta' paniku, instabilta` emozzjonali/tibdil fil-burdati, agitazzjoni;
English: • amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia
Maltese: • amneżija (telf ta' memorja),impediment tal- memorja (tinsa), ko-ordinazzjoni abnormali/ataxja (impediment fil-movimenti ko-ordinati), paraesteżja (tingiż), disturbi fl-attenzjoni (telf ta'konċentrazzjoni);
English: Peak concentrations (Cmax) are typically 31 and 43 μg/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively.
Maltese: (Cmax) huma ssoltu 31μg/ml wara doża waħda ta' 1,000 mg u 43 μg/ml wara doża ripetuta ta' 1,000 mg darbtejn kuljum.
English: Levetiracetam Teva 750 mg contains the colouring agent sunset yellow (E110) that may cause allergic reactions.
Maltese: Levetiracetam Teva 750 mg fih Sunset Yellow FCF (E110) sustanza li tgħati l-kulur tista' tikkawża reazzjonijiet allerġiċi.
English: Infants 6 to 23 months, children and adolescents weighing less than 50 kg
Maltese: Trabi ta' bejn 6 sa 23 xahar, tfal u adoloxxenti li jiżnu inqas minn 50 kg
English: How to store Levetiracetam Teva Contents of the pack and other information
Maltese: Kontenut tal-pakkett u informazzjoni oħra
English: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam).
Maltese: Suwiċidju, attentat ta' suwiċidju, ħsibijiet u mġiba suwiċidali kienu rrappurtati f'pazjenti trattati b'mediċini ta' kontra l-epilessija (inkluż levetiracetam).
English: Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention
Maltese: iperkinesja, diffikultà fil mixi, enċefalopatija abnormali/ataxja, paraestesija, disturbi flattenzjoni
English: 305, 74770 Opava-Komarov
Maltese: Pianezza, Italy 305, 74770
English: 58.3 % of the levetiracetam treated patients and 23.3 % of the patients on placebo had at least a 50 % reduction in myoclonic seizure days per week.
Maltese: 58.3 % tal-pazjenti trattati b'levetiracetam u 23.3 % tal-pazjenti fuq plaċebo kellhom mill-inqas 50 %
English: 10 to 20 mg/kg twice daily
Maltese: 10 sa 20 mg/kg darbtejn kuljum
English: The primary measure of effectiveness was the responder rate (percent of patients with ≥ 50 % reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG.
Maltese: Il-kejl primarju ta' effettività kienet ir-rata ta' pazjenti li rrispondew (persentaġġ tal-pazjenti b'≥ 50 % tnaqqis mill-linja bażi fil-frekwenza tal-medda ta' aċċessjonijiet tat-tip partial onset f'ġurnata) mkejla b'blinded central reader bl'użu ta' vidjo EEG ta' 48 siegħa.
English: In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.
Maltese: Levetiracetam m'għandu ebda effett ukoll fuq il-glukuronidazzjoni ta' valproic acid in vitro.
English: • skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (StevensJohnson syndrome), and a more severe form causing skin peeling in more than 30 % of the body surface (toxic epidermal necrolysis).
Maltese: • raxx fil-ġilda, li jista' jifforma bżieżaq u li jidher qisu targi żgħar (tikek ċentrali skuri mdawwra b'erja iżjed pallida, b'ċirku skur mat-tarf) (erythema multiforme), raxx diffuz bil-bżieżaq u ġilda li titqaxxar, partikolarrment madwar il-ħalq, mnieħer, għajnejn u l-ġenitali (sindrome ta' Stevens-Johnson), u forma iżjed severa li tikkawża ġilda li titqaxxar f'iżjed minn 30% tal-wiċċ tal-ġilda (nekroliżi tossiku epidermali);
English: (2) Following dialysis, a 250 to 500 mg supplemental dose is recommended.
Maltese: (2) Wara d-dijaliżi, hija rrikkmandata doża supplimentari ta' bejn 250 u 500 mg.
English: In patients aged 4-16 years, a total of 645 patients have been treated with levetiracetam in placebo-controlled and open label extension studies.
Maltese: F'pazjenti ta' eta` ta' 4-16-il sena, total ta' 645 pazjent kienu trattati b'levetiracetam f'studji ta' estenzjoni open label u kkontrollati bil-plaċebo. 233
English: How to take Levetiracetam Teva
Maltese: Tiħux Levetiracetam Teva
English: 10 to 30 mg/kg twice daily
Maltese: 10 sa 30 mg/kg darbtejn kuljum
English: Levetiracetam Teva 1000 mg film-coated tablets EU/1/11/701/022
Maltese: Levetiracetam Teva 1000 mg pilloli miksija b'rita EU/1/11/701/022
English: Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6 - 17 the MRHD on a mg/m2 basis).
Maltese: Studji fl-annimali tat-twelid u ġovanili fil-firien u l-klieb urew li ma kienx hemm effetti avversi fil punti tat-tmiem standard tal-iżvilupp jew maturazzjoni b'dożi sa 1800 mg/kg/ġurnata (x 6 - 17-il MRHD fuq bażi ta' mg/m2).
English: 7 to 14 mg/kg twice daily
Maltese: 7 sa 14 mg/kg darbtejn kuljum
English: Levetiracetam Teva 250 mg film-coated tablets levetiracetam
Maltese: Levetiracetam Teva 250 mg pilloli miksija b'rita levetiracetam
English: Excipient with known effect: Each film-coated tablet contains 0.35 mg colouring agent sunset yellow (E110).
Maltese: Kull pillola miksija b'rita fiha 0.35 mg ta' sustanza koloranti sunset yellow (E110).
English: CLcr (ml/min) = [140-age(years)] x weight (kg)_ (x 0.85 for women)
Maltese: 50 kg jew aktar, billi tuża din il-formula: [140 -età (snin)] x piż (kg)
English: Cough thoracic and mediastinal disorders Gastrointestinal disorders
Maltese: Disturbi gastrointestinali